Introduction
============

Renal cell carcinoma (RCC) is the most common renal malignancy, causing approximately 99200 new cases and almost 39100 deaths in Europe in 2018 ([@b1-ol-0-0-11408]). Clear cell renal cell carcinoma (ccRCC) is the most common pathological type of RCC, accounting for 80--90% of total cases globally in 2016 ([@b2-ol-0-0-11408]). Although surgical resection is an effective treatment option for early ccRCC, the prognosis for patients with metastatic ccRCC is poor ([@b3-ol-0-0-11408]). Targeted therapy is a promising anticancer strategy ([@b4-ol-0-0-11408]) and the identification of novel hub genes specific to ccRCC may improve targeted treatment and confer significant benefit on patients.

MYB protooncogene-like 2 (*MYBL2*), a member of the myeloblastosis family of transcription factors, influences numerous factors affecting cell cycle progression ([@b5-ol-0-0-11408]). Recently, an increasing number of studies have demonstrated that *MYBL2* expression is significantly associated with various carcinomas. For example, upregulated *MYBL2* expression was identified in gastric cancer and predicted a poor prognosis, indicating that *MYBL2* may serve as a promising biomarker ([@b6-ol-0-0-11408]). Overexpressed MYBL2 promotes proliferation and inhibits apoptosis of breast cancer cells targeted by miR-143-3p ([@b7-ol-0-0-11408]). Moreover, *MYBL2* knockdown suppressed the growth of esophageal squamous cell and colorectal carcinoma cells via regulation of the cell cycle ([@b8-ol-0-0-11408]). In other cancer types, including hepatocellular carcinoma (HCC) ([@b9-ol-0-0-11408]), non-small cell lung cancer (NSCLC) ([@b10-ol-0-0-11408]) and pancreatic ductal adenocarcinoma ([@b11-ol-0-0-11408]), high *MYBL2* expression also promoted the progression of tumors and resulted in a poorer prognosis. However, the influence of *MYBL2* expression on ccRCC is yet to be elucidated.

Therefore, *MYBL2* expression was analyzed in ccRCC, and the association between *MYBL2* and the prognosis of patients with ccRCC was determined in the current study. Moreover, gene set enrichment analysis (GSEA) was performed to investigate the biological functions of *MYBL2* in ccRCC. According to previous studies, it was hypothesized that *MYBL2* may independently predict the prognosis of ccRCC patients and may represent a novel therapeutic target.

Materials and methods
=====================

### Patient samples

The mRNA expression data and corresponding clinical data from patients with ccRCC were downloaded from the official website of The Cancer Genome Atlas database (National Institutes of Health), dataset TCGA-Kidney Renal Clear Cell Carcinoma. A total of 611 gene expression data profiles and 537 clinical data profiles were retrieved from TCGA ccRCC database in July 2019. The 611 gene expression data profiles were used to evaluate the differential expression of *MYBL2* between tumor (539) and healthy tissues (72). Subsequently, patients lacking gene expression data or all clinicopathological characteristics were excluded, 530 ccRCC profiles with both gene expression and clinical data were included for further analysis. Some patients had incomplete clinicopathological characteristics data, such as T stage ([@b12-ol-0-0-11408]), therefore these patients were included in analysis of clinical information they possessed, but excluded in the analysis of clinicopathological characteristics they lacked. Hence, some variables in [Table I](#tI-ol-0-0-11408){ref-type="table"} do not total 530.

### GSEA

GSEA was used to investigate the potential functions of *MYBL2* in ccRCC. The pretense of GSEA is to use predefined gene sets (usually from functional annotation or results of previous studies) to rank genes according to the degree of differential expression in two types of samples, and then test whether the preselected gene sets are enriched at the top or bottom of this ranking table. In the present study, the 'c2.cp.kegg.v6.2.symbols.gmt' gene sets from the Molecular Signatures Database ([software.broadinstitute.org/gsea/msigdb/index.jsp](software.broadinstitute.org/gsea/msigdb/index.jsp)) were analyzed using GSEA 3.0 software (BROAD Institute). To obtain normalized enrichment scores (NESs), the nominal P-value and false discovery rate (FDR) q-value were determined. The number of gene set permutations for each analysis was set at 1,000, and the phenotype label was the expression level of *MYBL2*. Gene sets with a nominal P-value of \<0.05 and an FDR q-value of \<0.25 were considered significantly enriched ([@b13-ol-0-0-11408]).

### Statistical analysis

The Mann-Whitney U test was used to compare MYBL2 expression in tumor and healthy tissues. The Wilcoxon signed-rank test was used to compare MYBL2 expression in paired tissues. To examine the association between clinicopathological factors and MYBL2 expression (after excluding healthy tissue sample data) the Mann-Whitney U test was performed for comparison between two groups (sex, lymph node metastasis and distant metastasis), and the Kruskal-Wallis test and Bonferroni\'s post-hoc test was performed for multi-group comparison \[tumor (T) stage, clinical stage and histological grade\] ([@b12-ol-0-0-11408]), then logistic regression was conducted for further analysis. The median value of MYBL2 expression was selected as the cutoff value, and patients with ccRCC were subsequently divided into high- and low-expression groups. Kaplan-Meier survival curves were constructed and log rank tests performed to evaluate the association between MYBL2 expression and overall survival (OS). A univariate Cox regression analysis was performed to explore the association of clinicopathological factors and MYBL2 expression with OS, and a multivariate Cox regression analysis was performed to investigate whether MYBL2 can independently influence prognosis. All statistical analyses were performed using R version 3.5.3 software ([@b14-ol-0-0-11408]), Statistical Product and Service Solutions (SPSS) 26.0 software (IBM Corp.) and GraphPad Prism 8.0.2 software (GraphPad Software).

Results
=======

### Patient characteristics

Of the 530 included patients, the median patient age was 61 years (range, 26--90), and there were 14, 227, 206 and 75 patients with histological grade I, II, III and IV, respectively. A total of 265, 57, 123 and 82 patients presented with clinical stage I, II, III and IV, respectively. There were also 271, 69, 179 and 11 patients with T1, T2, T3 and T4, respectively. Notably, 239 and 16 patients presented with node (N)0 and N1, respectively, and there were 420 and 78 patients with metastasis (M)0 and M1, respectively. The characteristics of the included patients with ccRCC are summarized in [Table I](#tI-ol-0-0-11408){ref-type="table"}. A number of samples retrieved from TCGA had incomplete clinicopathological characteristics, therefore, samples lacking specific clinicopathological characteristics will be excluded when these clinicopathological characteristics were counted.

### Upregulation of MYBL2

It was revealed that *MYBL2* was significantly upregulated in ccRCC tissues (P\<0.001; [Fig. 1A](#f1-ol-0-0-11408){ref-type="fig"}). In addition, *MYBL2* was also significantly upregulated in ccRCC tissues compared with paired healthy tissues (P\<0.001; [Fig. 1B](#f1-ol-0-0-11408){ref-type="fig"}). The data from [Fig. 1A and B](#f1-ol-0-0-11408){ref-type="fig"} were derived from TCGA.

### Association of MYBL2 expression and clinicopathological factors

The median value of *MYBL2* expression was selected as the cut-off value and patients with ccRCC were divided into high- and low-expression groups. The median follow-up times for the high- and low-*MYBL2* expression groups were 967 and 951 months, respectively. As indicated in [Fig. 2A-F](#f2-ol-0-0-11408){ref-type="fig"}, the upregulation of *MYBL2* was significantly associated with sex, an advanced T stage, lymph node metastasis, distant metastasis, clinical stage and histological grade. Logistic regression demonstrated that increased *MYBL2* expression was significantly associated with age, sex, histologic grade, clinical stage, T stage, lymph node metastasis and distant metastasis ([Table II](#tII-ol-0-0-11408){ref-type="table"}). The data from [Fig. 2A-F](#f2-ol-0-0-11408){ref-type="fig"} was derived from TCGA.

### MYBL2 can be considered a prognostic factor for ccRCC

Kaplan-Meier analysis revealed that patients with ccRCC with high *MYBL2* expression exhibited a poorer OS rate compared with the low-expression group ([Fig. 2G](#f2-ol-0-0-11408){ref-type="fig"}). Moreover, the univariate Cox regression analysis indicated that high *MYBL2* expression was strongly associated with a poor prognosis. Other clinical variables, such as age, grade, stage, T stage, lymph node metastasis and distant metastasis were all associated with OS. Moreover, multivariate analysis revealed that high *MYBL2* expression, age and distant metastasis were independently associated with a poor prognosis ([Table III](#tIII-ol-0-0-11408){ref-type="table"}). Therefore, *MYBL2* may be an independent prognostic biomarker for patients with ccRCC.

### Biological pathogenesis of MYBL2 in ccRCC

GSEA revealed that the 'intestinal immune network for IgA production', 'primary immunodeficiency', 'the janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway', 'the cytosolic DNA-sensing pathway', 'the p53 signaling pathway' and 'the chemokine signaling pathway' ([Fig. 3A-F](#f3-ol-0-0-11408){ref-type="fig"}) were enriched in the high *MYBL2* expression datasets ([Table IV](#tIV-ol-0-0-11408){ref-type="table"}).

Discussion
==========

In the present study, analyzing the data from TCGA provided a direction for further research and generated genomic and statistical evidence to support novel candidate cancer targets for therapeutic and diagnostic development. In the current study, it was revealed that the upregulation of MYBL2 was significantly associated with sex, high histological grade, advanced clinical stage, T stage, lymph node metastasis, distant metastasis and poor OS rate, and may therefore be used as an independent prognostic factor for patients with ccRCC, according to data from TCGA. Furthermore, the results of GSEA demonstrated that MYBL2 upregulation was significantly associated with classical tumor-associated pathways and immune-associated pathways.

Previous findings have demonstrated that *MYBL2* regulates the progression of malignant tumors by inhibiting the cell cycle and activating tumor-associated genes and pathways via transcription factor activity ([@b15-ol-0-0-11408]). The upregulation of *MYBL2* has been reported in various cancer types, suggesting that *MYBL2* may promote tumorigenesis. For example, the upregulation of *MYBL2* was revealed to promote progression of the G1-S phase transition by suppressing insulin-like growth factor-binding protein 3; thus, *MYBL2* may represent a novel therapeutic biomarker in NSCLC ([@b16-ol-0-0-11408]). Other findings indicated that *MYBL2* regulated breast cancer cell proliferation and apoptosis via the targeting of microRNA-143-3p ([@b7-ol-0-0-11408]). Therefore, *MYBL2* may serve as an effective therapeutic target. Notably, the high expression and carcinogenic effects of *MYBL2* in ccRCC were described in detail in the present study.

GSEA was then performed; it is able to detect the expression changes in gene sets rather than in individual genes and is considered more flexible and reliable than traditional methods, such as Gene Ontology and Kyoto Encyclopedia of Genes and Genomes, making it one of the most commonly used pathway analysis methods to study the biological function of tumors ([@b17-ol-0-0-11408]). However, for genes with complex interactions and insufficient annotation information, the sensitivity of GSEA is reduced due to functional class scoring, the approach of GSEA ([@b18-ol-0-0-11408]). GSEA demonstrated that *MYBL2* is involved in various pathways associated with tumor progression, such as the intestinal immune network for IgA production, primary immunodeficiency, the JAK/STAT signaling pathway, the cytosolic DNA-sensing pathway, the p53 signaling pathway and the chemokine signaling pathway. Some of these pathways have been reported to be associated with other cancer types. In HCC cells, increased apolipoprotein B mRNA editing enzyme catalytic subunit 3F expression promoted cell proliferation and migration, which were mediated by immune-associated pathways ([@b19-ol-0-0-11408]). Moreover, a high incidence of cancer, especially lymphoma, has been reported in subjects with primary immunodeficiency ([@b20-ol-0-0-11408]). Numerous studies have reported the association between JAK/STAT and various malignancies and inflammatory pathologies, suggesting that JAK-targeted drugs may be successful for the treatment of cancer and immune-mediated diseases ([@b21-ol-0-0-11408]--[@b27-ol-0-0-11408]). A previous study indicated that the downregulation of *MYBL2* caused cell cycle arrest at the G~2~/M phase via the p53-p21-DREAM-CDE/CHR pathway ([@b28-ol-0-0-11408]).

However, there were still certain limitations to the current study. Notably, the number of normal tissues was significantly lower than the number of tumorous tissues retrieved from TCGA database. The factors associated with patient prognosis, such as the use of drugs, surgical treatment and surgical details, were lacking. Moreover, the protein levels or direct mechanisms underlying the role of *MYBL2* in ccRCC could not be assessed using TCGA database. Therefore, accounting for various confounding factors to more accurately assess the association between *MYBL2* and OS, and exploring the specific molecular mechanisms involved represent a promising focus for future research.

In conclusion, it was revealed that the upregulation of *MYBL2* in ccRCC was associated with certain advanced clinical factors and was able to independently predict a poor prognosis, indicating that *MYBL2* expression may represent a promising biomarker and potential therapeutic target for the treatment of patients with ccRCC. However, the protein expression levels of MYBL2 and the specific molecular mechanisms underlying poor prognosis of ccRCC need to be further explored in future research.
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![Comparison of *MYBL2* expression between ccRCC and healthy tissues using data from The Cancer Genome Atlas. A Mann-Whitney U test was used to compare MYBL2 expression between tumor and healthy tissues. A Wilcoxon signed-rank test was used to compare MYBL2 expression in paired tumor and non-tumorous tissues. (A) The expression of *MYBL2* in ccRCC tissues (n=537) was significantly higher compared with normal tissues (n=72). (B) Compared with 72 paired normal tissues, ccRCC tissues exhibited significant upregulation of *MYBL2*. \*\*\*P\<0.001. ccRCC, clear cell renal cell carcinoma.](ol-19-04-2765-g00){#f1-ol-0-0-11408}

###### 

Analysis of TGCA datasets was conducted to determine expression of *MYBL2* and its association with clinicopathological variables. The median value of *MYBL2* expression was considered the cutoff value. To examine the association between clinicopathological factors and *MYBL2* expression after excluding normal sample data, the Mann-Whitney U test was performed for comparison between two groups \[sex, N stage and M stage ([@b12-ol-0-0-11408])\], the Kruskal-Wallis test was used for multigroup comparison \[T stage, clinical stage and histological grade ([@b12-ol-0-0-11408])\]. The association between *MYBL2* expression and OS was estimated using Kaplan-Meier survival curves. (A) Sex; (B) T stage; (C) N stage; (D) M stage; (E) histological grade; and (F) clinical stage. (G) Kaplan-Meier curves revealed that the prognosis of patients with ccRCC with high *MYBL2* expression was poorer than that of patients with ccRCC with low *MYBL2* expression. \*P\<0.05, \*\*\*P\<0.001 TGCA, The Cancer Genome Atlas; ccRCC, clear cell renal cell carcinoma; *MYBL2*, MYB protooncogene-like 2; T, tumor; N, node; M, metastasis.
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![Enrichment plots from GSEA. GSEA was conducted to identify the differentially activated signaling pathways in the high *MYBL2* expression ccRCC datasets. GSEA revealed that (A) 'the intestinal immune network for IgA production', (B) 'primary immunodeficiency', (C) 'the janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway', (D) 'the cytosolic DNA-sensing pathway', (E) 'the p53 signaling pathway' and (F) 'the chemokine signaling pathway' were significantly enriched in patients with upregulated *MYBL2* expression. The data from (A-F) were derived from GSEA. ccRCC, clear cell renal cell carcinoma; *MYBL2*, MYB protooncogene-like 2; GSEA, gene set enrichment analysis; NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate; q-val, q-value.](ol-19-04-2765-g03){#f3-ol-0-0-11408}

###### 

Clinicopathological characteristics of patients with clear cell renal cell carcinoma, retrieved from The Cancer Genome Atlas database.

  Clinical characteristics                                                         Value
  -------------------------------------------------------------------------------- -------------
  Median age at diagnosis, years (range)                                           61 (21--90)
  Sex, %                                                                           
    Female                                                                         35.1
    Male                                                                           64.9
  Histological grade^[a](#tfn1-ol-0-0-11408){ref-type="table-fn"}^, %              
    I                                                                                2.7
    II                                                                             43.5
    III                                                                            39.5
    IV                                                                             14.3
  Clinical stage^[a](#tfn1-ol-0-0-11408){ref-type="table-fn"}^, %                  
    I                                                                              50.3
    II                                                                             10.8
    III                                                                            23.3
    IV                                                                             15.6
  T stage^[a](#tfn1-ol-0-0-11408){ref-type="table-fn"}^, %                         
    T1                                                                             51.1
    T2                                                                             13.1
    T3                                                                             33.8
    T4                                                                             0.02
  Lymph node metastasis N stage^[a](#tfn1-ol-0-0-11408){ref-type="table-fn"}^, %   
    N0                                                                             93.7
    N1                                                                               6.3
  Distant metastasis M stage^[a](#tfn1-ol-0-0-11408){ref-type="table-fn"}^, %      
    M0                                                                             84.3
    M1                                                                             15.7

(ref. [@b12-ol-0-0-11408]). T, tumor; N, node; M, metastasis.

###### 

Association of MYB protooncogene-like 2 expression levels with the clinicopathological factors of patients using logistic regression analysis.

  Clinical characteristics                                                     Total, n   Odds ratio for MYBL2 expression (Confidence Interval)   P-value
  ---------------------------------------------------------------------------- ---------- ------------------------------------------------------- -------------------------------------------------------
  Age, years                                                                   530        0.98 (0.96--0.99)                                       0.003^[b](#tfn3-ol-0-0-11408){ref-type="table-fn"}^
  Sex, male vs. female                                                         530        1.54 (1.08--2.21)                                       0.018^[a](#tfn2-ol-0-0-11408){ref-type="table-fn"}^
  Histological grade^[d](#tfn5-ol-0-0-11408){ref-type="table-fn"}^, IV vs. I   89         22.15 (5.36--151.97)                                    \<0.001^[c](#tfn4-ol-0-0-11408){ref-type="table-fn"}^
  Clinical stage^[d](#tfn5-ol-0-0-11408){ref-type="table-fn"}^, IV vs. I       347        2.99 (1.78--5.11)                                       \<0.001^[c](#tfn4-ol-0-0-11408){ref-type="table-fn"}^
  T stage^[d](#tfn5-ol-0-0-11408){ref-type="table-fn"}^, T4 vs. T1             530        6.19 (1.56--41.15)                                      0.021^[a](#tfn2-ol-0-0-11408){ref-type="table-fn"}^
  N stage^[d](#tfn5-ol-0-0-11408){ref-type="table-fn"}^, N1 vs. N0             255        4.91 (1.54--21.83)                                      0.015^[a](#tfn2-ol-0-0-11408){ref-type="table-fn"}^
  M stage^[d](#tfn5-ol-0-0-11408){ref-type="table-fn"}^, M1 vs. M0             498        3.85 (1.39--2.29)                                       0.001^[b](#tfn3-ol-0-0-11408){ref-type="table-fn"}^

P\<0.05

P\<0.01

P\<0.001.

(ref. [@b12-ol-0-0-11408]). Patients were stratified into high- and low-expression groups, with the median expression level selected as the cut-off value. T, tumor; N, node; M, metastasis.

###### 

Association of OS and clinicopathological characteristics in patients from TCGA database using Cox regression.

                                                                     Univariate analysis   Multivariate analysis                                                                               
  ------------------------------------------------------------------ --------------------- ----------------------- ------------------------------------------------------- ------ ------------ -----------------------------------------------------
  Age, years                                                         1.02                  1.00--1.04              0.012^[a](#tfn6-ol-0-0-11408){ref-type="table-fn"}^     1.03   1.01--1.05   0.001^[b](#tfn7-ol-0-0-11408){ref-type="table-fn"}^
  Sex, male vs. female                                               1.01                  0.67--1.54              0.951                                                   1.11   0.71--1.73   0.657
  MYB protooncogene-like 2 expression, high vs. low                  1.52                  1.29--1.78              \<0.001^[c](#tfn8-ol-0-0-11408){ref-type="table-fn"}^   1.29   1.08--1.55   0.004^[b](#tfn7-ol-0-0-11408){ref-type="table-fn"}^
  Histological grade^[d](#tfn9-ol-0-0-11408){ref-type="table-fn"}^   2.24                  1.68--2.99              \<0.001^[c](#tfn8-ol-0-0-11408){ref-type="table-fn"}^   1.27   0.91--1.79   0.164
  Clinical stage^[d](#tfn9-ol-0-0-11408){ref-type="table-fn"}^       1.86                  1.54--2.25              \<0.001^[c](#tfn8-ol-0-0-11408){ref-type="table-fn"}^   1.11   0.71--1.74   0.645
  T stage^[d](#tfn9-ol-0-0-11408){ref-type="table-fn"}^              3.31                  2.17--5.06              \<0.001^[c](#tfn8-ol-0-0-11408){ref-type="table-fn"}^   1.61   0.77--3.38   0.208
  N stage^[d](#tfn9-ol-0-0-11408){ref-type="table-fn"}^              2.93                  1.52--5.67              0.001^[b](#tfn7-ol-0-0-11408){ref-type="table-fn"}^     1.31   0.64--2.68   0.456
  M stage^[d](#tfn9-ol-0-0-11408){ref-type="table-fn"}^              4.07                  2.63--6.30              \<0.001^[c](#tfn8-ol-0-0-11408){ref-type="table-fn"}^   2.25   1.03--4.79   0.041^[a](#tfn6-ol-0-0-11408){ref-type="table-fn"}^

P\<0.05

P\<0.01

P\<0.001.

(ref. [@b12-ol-0-0-11408]). HR, hazard ratio; CI, confidence interval; T, tumor; N, node; M, metastasis.

###### 

Gene sets enriched in the high-MYB protooncogene-like 2 expression phenotypes.

  Gene set name                                       NES     NOM P-value                                              FDR q-value
  --------------------------------------------------- ------- -------------------------------------------------------- -------------
  KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION   2.202   \<0.001^[b](#tfn11-ol-0-0-11408){ref-type="table-fn"}^   \<0.001
  KEGG_PRIMARY_IMMUNODEFICIENCY                       2.146   \<0.001^[b](#tfn11-ol-0-0-11408){ref-type="table-fn"}^   \<0.001
  KEGG_JAK_STAT_SIGNALING_PATHWAY                     1.999   \<0.001^[b](#tfn11-ol-0-0-11408){ref-type="table-fn"}^   0.005
  KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY                  1.993   \<0.001^[b](#tfn11-ol-0-0-11408){ref-type="table-fn"}^   0.004
  KEGG_CHEMOKINE_SIGNALING_PATHWAY                    1.953   0.002^[a](#tfn10-ol-0-0-11408){ref-type="table-fn"}^     0.006
  KEGG_P53_SIGNALING_PATHWAY                          1.948   0.002^[a](#tfn10-ol-0-0-11408){ref-type="table-fn"}^     0.006

P\<0.01

P\<0.001. Gene sets with NOM P-value \<0.05 and FDR q-value \<0.25 were considered significant. NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate; JAK-STAT, janus kinase-signal transducer and activator of transcription; KEGG, Kyoto Encyclopedia of Genes and Genomes.
